Provided by Tiger Trade Technology Pte. Ltd.

Nuvectis Pharma, Inc.

21.92
+1.205.79%
Post-market: 21.70-0.2200-1.00%19:30 EDT
Volume:207.52K
Turnover:4.50M
Market Cap:714.19M
PE:-16.80
High:22.00
Open:21.11
Low:21.04
Close:20.72
52wk High:29.28
52wk Low:5.55
Shares:32.58M
Float Shares:21.23M
Volume Ratio:1.16
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3045
EPS(LYR):-1.3236
ROE:-214.58%
ROA:-73.07%
PB:78.64
PE(LYR):-16.56

Loading ...

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights With Haisco Pharmaceutical Group for Two Potentially Best-in Class Clinical-Stage Compounds

THOMSON REUTERS
·
Jun 22

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

GlobeNewswire
·
Jun 22

Nuvectis Shareholders Approve Director Election and Auditor Ratification

TIPRANKS
·
Jun 13

Nuvectis Pharma shareholders approve auditor ratification at annual meeting

Reuters
·
Jun 13

Nuvectis Pharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 13

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 13

Nuvectis Pharma, Inc. : H.c. Wainwright Raises Target Price to $13 From $10

THOMSON REUTERS
·
Jun 13

Analyst Reiterates Buy on Nuvectis Pharma, Maintains $17 Price Target on NXP900 Pipeline Upside and Favorable M&A Read‑Through

TIPRANKS
·
Jun 11

Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

GlobeNewswire
·
May 14

Analysts’ Top Healthcare Picks: Precision BioSciences (DTIL), Nuvectis Pharma (NVCT)

TIPRANKS
·
May 07

Nuvectis Pharma Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 05

Nuvectis Pharma Q1 EPS $(0.26) Beats $(0.32) Estimate

Benzinga Earnings
·
May 05

Nuvectis Q1 FY26 net loss widens to USD 6.1 million

Reuters
·
May 05

BRIEF-Nuvectis Pharma Q1 EPS USD -0.26

Reuters
·
May 05

Press Release: Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

Dow Jones
·
May 05

Nuvectis Pharma Inc expected to post a loss of 31 cents a share - Earnings Preview

Reuters
·
May 01

Nuvectis Pharma announces annual shareholder meeting

Reuters
·
Apr 28

Nuvectis to present Phase 1b NXP900 data at AACR meeting in April

Reuters
·
Apr 01

BRIEF-Nuvectis Pharma Announces Upcoming Presentations For Nxp900 At The 2026 American Association

Reuters
·
Mar 31